Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273SARS-CoV-2의 면역 역학은 면역 억제된 류마티스 관절염 또는 mRNA-1273 예방 접종을 받은 다발성 경화증 환자를 경험했습니다.Article Published on 2022-07-152022-09-12 Journal: eLife [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] absence acute respiratory syndrome affected analyzed anti-CD20 antibody Autoimmune Autoimmune disease Autoimmune diseases B cell response benefit CD4 CD8 Cell cellular cellular immunity central memory circulating condition coronavirus COVID-19 COVID-19 mRNA vaccine development disease Disease activity European European Commission first vaccination flow cytometry follicular HCs healthy control Horizon Human humanized humoral Humoral immunity IgG immune immune response Immunity immunology Immunosuppressant immunosuppressants Immunosuppressed increased risk Infection Inflammation leadership longitudinal marker Medicine methotrexate Moderna monoclonal antibody monotherapy mRNA mRNA-1273 MTX multiple sclerosis Netherland organization outcome Patient patients treated preserved recall Research resulting rheumatoid arthritis SARS-CoV-2 second vaccination shielding significantly supported suppress sustained T cell T cell response T cells T helper the SARS-CoV-2 treated Treatment union vaccination Vaccine vulnerable patients whole blood sample [DOI] 10.7554/eLife.77969 PMC 바로가기 [Article Type] Article
Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases만성 폐질환 환자에서 BNT162b2 COVID-19 백신 2회 접종 후 손상된 면역학적 결과와 관련된 항체 반응 및 위험 인자Article Published on 2022-07-012022-09-12 Journal: BMJ Open Respiratory Research [Category] MERS, 진단, [키워드] 1:1 1.26 95% CI adjusted antibody concentration Antibody Response aRR association Asthma bronchiectasis Charlson Comorbidity Index chronic pulmonary disease cohort study Comorbidity Control controls copd epidemiology COVID-19 COVID-19 vaccination COVID-19 vaccine defined dose Factor fibrosis first vaccination functional geometric healthcare personnel Humoral response identify immunological immunological responses Immunosuppression immunosuppressive Inclusion increasing age Interaction interstitial Interstitial Fibrosis lowest mRNA neutralising neutralising antibody of BNT162b2 outcome Patient Poisson regression Prednisolone Primary outcome Prospective quartile Receptor binding domain reported Responder response responses risk risk factor secondary outcome tested vaccination [DOI] 10.1136/bmjresp-2022-001268 PMC 바로가기 [Article Type] Article
Antibody response to the messenger RNA-1273 vaccine (Moderna) in liver transplant recipients간 이식 환자에서 메신저 RNA-1273 백신(모더나)에 대한 항체 반응Article Published on 2022-07-012022-09-12 Journal: Hepatology communications [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Administered anti-S anti-S IgG antibody cause clinical coronavirus coronavirus disease COVID-19 COVID-19 infection develop dose evaluated examined Factor first vaccination Follow-up General population Hepatitis IgG Immunoglobulin Immunological response immunosuppressive include interquartile range laboratory data liver Liver transplantation Logistic regression LTR LTRs median median age men Messenger RNA Moderna MOST Most patient mRNA mRNA-1273 vaccine mRNA-based vaccine Odds ratio Patient positive predict receiving recipient recipients regimen response RNA-1273 SARS-CoV-2 Serologic response shown tested the spike protein the vaccine university Vaccine vaccine dose [DOI] 10.1002/hep4.1937 PMC 바로가기 [Article Type] Article
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases자가 면역 전신 질환 환자에서 COVID-19 백신의 추가 용량에 대한 부재 또는 차선책 반응Observational Study Published on 2022-07-012022-09-12 Journal: Journal of autoimmunity [Category] MERS, 임상, 진단, [키워드] administration antibody ASD Autoimmune Autoimmune systemic diseases BNT162b2 booster dose Booster vaccine Control controls COVID-19 COVID-19 vaccine COVID-19 vaccines Cryoglobulinemic vasculitis dose effective elicited evaluated exhibiting first vaccination Follow-up identify increased risk individual Infection mRNA COVID-19 vaccine mRNA-1273 multicenter Neutralizing antibodies Patient patients persistence Rheumatoid rheumatoid arthritis Seroconversion serum significantly significantly higher significantly increased systemic systemic disease Systemic lupus Systemic sclerosis systemic vasculitis the mean therapeutic strategy Treatment vaccination Vaccine [DOI] 10.1016/j.jaut.2022.102866 PMC 바로가기 [Article Type] Observational Study
Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID장기 코로나 환자에서 1회 접종 후 증상 변화와 항체가와의 관계Article Published on 2022-07-012022-09-12 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Abnormalities addressed antibody Antibody titer change changes in Coronavirus disease 2019 COVID COVID-19 enrolled evaluated excessive immune response fatigue first vaccination groups highest hospital joint Long Long COVID median men olfactory Pain Patient patients postvaccination Ratio relationship SARS-CoV-2 IgG significantly single vaccination Symptom vaccination Vaccine were measured worsened worsening [DOI] 10.1002/jmv.27689 PMC 바로가기 [Article Type] Article
SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection사전 감염 유무에 관계없이 단일 COVID-19 백신 접종 후 SARS-CoV-2 항체 궤적Article Published on 2022-06-292022-09-12 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] anti-Spike IgG antibody Antibody Response BNT162b2 ChAdOx1 COVID-19 Infection Survey COVID-19 vaccination dose evaluate Evidence first vaccination General population generate half-live incidence individual infected with SARS-CoV-2 Infection initial median mRNA-1273 population immunity producing receiving responses SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 vaccine significantly single vaccination Single-dose subsequent the median threshold trajectory vaccination Vaccinations Vaccine [DOI] 10.1038/s41467-022-31495-x PMC 바로가기 [Article Type] Article
Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial남아프리카의 Sisonke 연구에서 의료 종사자를 대상으로 한 단회 용량 Ad26.COV2.S 백신의 안전성 평가: 3b상 시행 시험Clinical Trial Published on 2022-06-212022-09-12 Journal: PLoS Medicine [Category] MERS, 임상, 진단, [키워드] 48 hour Ad26.COV2.S vaccine adverse event AEs African age body ache breakthrough infections categories clinical clinical trials collected COVID-19 COVID-19 infection death demonstrated Effectiveness eligible evaluated expected Fever Final first vaccination Frequency HCW HCWs headache healthcare healthcare worker hospitalisations Immune system disorder implementation Implementation study IMPROVE incidence rate increasing age Infection injection site pain janssen men morbidity MOST National nervous system disorder occurred Open-label Pan participant Participants Phase 3 trials reactogenicity reactogenicity event Registered registry reported SAE SAEs safety evaluation safety profile serious AE single-arm design South South Africa Support Symptoms syndrome System thrombosis Trial triggered vaccination Vaccine [DOI] 10.1371/journal.pmed.1004024 PMC 바로가기 [Article Type] Clinical Trial
Immunogenicity of COVID-19 Vaccination in Patients With End-Stage Renal Disease Undergoing Maintenance Hemodialysis: The Efficacy of a Mix-and-Match Strategy유지 혈액투석을 받고 있는 말기 신질환 환자에서 코로나19 백신 접종의 면역원성: 혼합 및 일치 전략의 효능Article Published on 2022-06-132022-09-12 Journal: Journal of Korean medical science [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] activity acute respiratory syndrome antibody analysis binding antibody blood sample ChAdOx1 collected comparable coronavirus coronavirus disease COVID-19 COVID-19 vaccine dose End-stage renal disease ESRD evaluate first vaccination healthy healthy individual Hemodialysis hospital immunogenicity Laboratory maintenance mix-and-match neutralizing antibody participant Patient quantified receiving recruited SARS-CoV-2 SARS-CoV-2 neutralizing antibody second dose serum and plasma significantly higher Spike protein Strategy the SARS-CoV-2 vaccination Vaccine vaccine dose were measured [DOI] 10.3346/jkms.2022.37.e180 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial6~17세 어린이 대상 ChAdOx1 nCoV-19(AZD1222) 백신의 안전성 및 면역원성: 2상 단일 맹검, 무작위, 대조 시험인 COV006의 예비 보고서Clinical Trial Published on 2022-06-112022-09-11 Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, [키워드] 95% CI administration Adults adverse event adverse events age All participants anti-SARS-CoV-2 IgG antibody Antibody titre antibody titres arbitrary unit assigned AstraZeneca AZD1222 baseline capsular Cellular responses ChAdOx1 ChAdOx1 nCoV-19 children chronic respiratory conditions Concentration Controlled trial COVID-19 COVID-19 vaccine COVID-19 vaccines Cutoff Department dose doses Efficacy enrolled Fever first dose first vaccination four group four groups geometric geometric mean geometric mean ratios Geometric means group half-maximal inhibitory concentration Humoral response humoral responses immune response immune responses immunogenic immunogenicity in some intramuscular dose introduced investigators ISRCTN Laboratory laboratory-confirmed Laboratory-confirmed COVID-19 Local nucleocapsid protein Pain and tenderness participant Participants peaked Phase 2 phase 3 study preliminary report Primary outcome prime and boost raised randomised Randomly receive receiving recruitment Registered remained reported resolved respiratory response Safety safety population SARS-CoV-2 second dose second vaccination secondary outcome Serious Adverse Event Serious Adverse Events seronegative seronegative participant seronegative participants seropositive serostatus single-blind stratified study drug study groups tenderness Tolerability treatment allocation Trial vaccination Vaccine Viral viral particle were recorded [DOI] 10.1016/S0140-6736(22)00770-X PMC 바로가기 [Article Type] Clinical Trial
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity선천성 면역이상이 있는 성인 환자에서 mRNA-1273 코로나19 백신의 면역원성Controlled Clinical Trial Published on 2022-06-012022-09-12 Journal: The Journal of Allergy and Clinical Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, [키워드] acute respiratory syndrome All participant antibodies antibody Antibody Response Antibody titer baseline binding Cellular immune response CID clinically cohorts comparable Complication complications Control coronavirus correlated COVID-19 COVID-19 vaccination COVID-19 vaccine CVID deficiencies deficiency dose first vaccination healthy controls humoral immune response Immunity immunodeficiency immunogenic immunogenicity immunosuppressive drug Inborn error inborn errors of immunity increased risk Level Mild mRNA-1273 mRNA-1273 COVID-19 vaccine multicenter Neutralizing antibodies Patient patient group patients patients with CVID phagocyte Primary immunodeficiency disorders SARS-CoV-2 second vaccination seroconversion rate T-cell T-cell Response the antibody response vaccination against COVID-19 Vaccinations were assessed X-linked agammaglobulinemia XLA [DOI] 10.1016/j.jaci.2022.04.002 PMC 바로가기 [Article Type] Controlled Clinical Trial